Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundBALB/c and C57BL/6; Stat6VT transgenic and IL-4-deficient lines backcrossed at least 10 generations to BALB/cFemalen = Not stated for the fibronectin ointment experiment; MC903 m…Topical ointment applied to the wounded ear10 micrograms of fibronectin per applicationFirst application immediately after wounding (day 1), second at 24 hours (day 2)
Model: Full-thickness 2 mm ear punch wound in mice with atopic dermatitis-like skin, either spontaneous (Stat6VT transgenic) or induced by topical MC903 (2 nmol in 25 microlitres per ear for 5 days, ears punched on day 6)
Topical fibronectin significantly improved wound closure in Stat6VT mice at day 5 relative to ointment alone, with modest effects in wild-type mice, although it only partially restored re-epithelialisation.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.